RecruitingPhase 1NCT05363826

Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Photolitec LLC
Principal Investigator
William R Potter, MA
Photolitec LLC
Intervention
photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)(combination_product)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Collaborators

Roswell Park Cancer Institute · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05363826 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma →

← Back to all trials